You cannot register for this webinar

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. With the global EP market projected to reach $7.4B in 2022 with a 10.4% growth rate, BioSig has commenced a targeted commercial release of its PURE EP™ System, generating its first commercial sale in December 2020. The Company’s first product is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP™ System received FDA 510(k) clearance in August 2018. Physicians using BioSig’s PURE EP™ System have successfully completed over 410 patient cases to date. Systems are currently installed at multiple locations, including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida campus, Massachusetts General Hospital, the University of Pennsylvania, and Deborah Heart and Lung Center.